摘要:
The preparation and use of 17-L-[(2'-O- ß-D-glucopyranosyl-p-Dglucopyranosyl)-oxy]-cis-9-octadecenoate, Lactonic and Open ring 17-L-[(2'-O-pD-glucopyranosyl-ß-D-glucopyranosyl)-oxy]-cis-9-octadecenoate, Methyl 17-L[(2'-O-ß-D-glucopyranosyl-ß-D-glucopyranosyl)-oxy]-cis-9-octadecenoate, Ethyl 17-L-[(2'-O-ß-D-glucopyranosyl-ß-D-glucopyranosyl)-oxy]-cis-9-octadecenoate, Hexyl 17-L-[(2'-O-ß-D-glucopyranosyl-p-D-glucopyranosyl)-oxy]-cis-9octadecenoate, Ethyl 17-L-[(2'-O-ß-D-glucopyranosyl-ß-D-glucopy ranosyl)-oxy]cis-9-octadecenoate-6'-acetate and Ethyl 17-L-[(2'-O-ß-D-glucopyranosyl-ß-DgIucopyranosyl)-oxy]-cis-9-octadecenoate-6' ,6'-diacetate sophorolipids as antifungal agents.
摘要:
A process is disclosed for clarifying an aqueous xanthan gum solution comprising treatment of the xanthan solution with at least one chelating agent, surfactant, organic acid, or a mixture thereof, and with a protease enzyme or a lysozyme and a protease enzyme. Also disclosed is a highly purified solid xanthan gum and compositions containing the same, wherein the gum is obtained from the clarified xanthan gum solution.
摘要:
A food or pharmaceutical composition including a liquid composition comprising the fermentation product of a biologically active substance, in a carbohydrate medium other than dairy whey wherein said fermentation product has not been subject to any drying steps prior to introduction into said food or pharmaceutical composition is provided.
摘要:
The invention concerns a bacterial strain which has lost its phytopathogenic character by inactivation of at least one virulence gene and preserved its capacity for producing exopolysaccharide.
摘要:
Variant xanthan gums, including non-acetylated, non-pyruvylated, non-acetylated and non-pyruvylated, and fully-acetylated xanthan gums. In addition, in vitro and in vivo methods for the synthesis of these gums are disclosed. Mutant Xanthomonas campestris strains useful in these synthesis are also specified.